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Abstract
Introduction: Previous studies have provided inconsistent results on whether variants in the MBL2 gene, coding
for the complement-activating mannan-binding lectin (MBL) protein, associate with rheumatoid arthritis (RA). We
re-evaluated this in context of the main environmental and genetic risk factors (smoking, HLA-DRB1 ‘shared
epitope’ (SE), PTPN22*620W), which predispose to rheumatoid factor (RF) and/or anti-citrullinated-protein antibody
(ACPA)-positive RA.
Methods: In this population-based EIRA study, rheumatoid factor (RF), ACPA, smoking, SE and PTPN22*620W status
was determined in incident RA cases and matched controls. MBL-high (n = 1330) and MBL-low (n = 1257)
genotypes predicting MBL levels were constructed from four promoter and exon-1 polymorphisms in the MBL2
gene. Odds ratios with 95% confidence interval (OR, 95% CI) were calculated by logistic regression. In extended
families (n = 316), previously reported data were re-analyzed, considering RF and smoking.
Results: MBL-high genotypes tended to be associated with RF-negative (OR = 1.20, 95% CI 0.96-1.51) but not RF-
positive (OR = 1.00, 95% CI 0.83-1.20) RA. Results divided by ACPA status did not differ. When stratified for smoking,
MBL-high genotype was strongly associated with RF-negative RA in never smokers (OR = 1.82, 95% CI 1.24-2.69)
but not in ever smokers (OR = 0.96, 95% CI 0.73-1.30). In never smokers, the association was observed in both the
RF-negative/ACPA-negative (OR = 1.67, 95% CI 1.10-2.55) and RF-negative/ACPA-positive subgroups (OR = 3.07,
95% CI 1.37-6.89), and remained on an SE/PTPN22*620W negative background. In the extended families, the
reported association between high MBL and RA was in fact confined to never smokers.
Conclusions: High MBL may predispose to RF-negative RA but only in individuals who have never smoked. This
illustrates the importance of phenotypic subgrouping in genetic studies.
Introduction
In recent years, it has become evident that the subsets
of rheumatoid arthritis (RA) that are autoantibody posi-
tive and negative, that is have rheumatoid factor (RF) or
anti-citrullinated peptide antibody (ACPA) or both, not
only differ clinically but also have distinct genetic and
environmental risk profiles [1]. Thus, the risk associated
with the strongest known environmental (smoking) and
genetic (HLA-DRB1 shared epitope, or SE) susceptibility
factors for RA seems to be restricted mainly to autoanti-
body-positive disease [2-4]. This also applies to several
other risk alleles, including PTPN22*620W [5], each
with only a modest effect on RA risk, whereas reports
for the autoantibody-negative RA subset are sparse [6].
The MBL2 gene is one of several candidate genes,
which have not yielded consistent risk association with
RA. The MBL2 gene codes for the mannan-binding lec-
tin (MBL) protein, which is part of innate immune
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defenses and is present in serum as well as in synovial
fluid [7]. MBL is a soluble pattern recognition receptor
that binds to sugar structures on microorganisms and
modified self structures, including dying host cells
(apoptotic/necrotic), immunoglobulins (agalactosylated
IgG and certain forms of IgM and IgA), and immune
complexes. Thus, MBL can bind potential arthritogenic
agents and, after activation of the complement system,
might induce inflammation within the joint [8,9]. Com-
mon variant alleles situated in both promoter and struc-
tural regions of the MBL2 gene influence the stability,
function, and serum levels of the MBL protein [9],
which can vary 10,000-fold between individuals but are
stable for each individual over time [10]. These variants
can be grouped together into MBL-high and MBL-low
genotypes, which are known to be associated with MBL
levels above and below the median population level
(approximately 1,000 μg/L), respectively [11].
In a study on extended RA families, we previously
found higher MBL levels in RA patients than in their
first-degree relatives and in unrelated controls [12]. The
RA patients also had increased frequency of MBL-high
genotypes in one case-control study [13], whereas other
studies have reported no association [14-20] or the
opposite association [21-23].
Taken together, variants in the MBL2 gene and its
protein product can be functionally relevant in RA
pathogenesis, but previous inconsistent findings need to
be reconsidered in light of the known etiological hetero-
geneity of this disease. Thus, we have investigated the
impact of genetic variants of MBL on RA risk by using
information from a large population-based case-control
study of incident RA (Epidemiological Investigation of
Rheumatoid Arthritis, or EIRA), and this enabled us to
dissect this criteria-based syndrome into subgroups on
the basis of autoantibody status and environmental
(smoking) and genetic (SE and PTPN22) risk factors
that are known to be associated mainly with the autoan-
tibody-positive form. We found that the MBL-high gen-
otype was associated with RF-negative RA but only in
individuals who had never smoked. Similar findings
were observed in the extended RA families [12], in
whom the reported association between high MBL levels
and RA was, in fact, confined to never smokers.
Materials and methods
Study group: The Epidemiological Investigation of
Rheumatoid Arthritis
The study is a population-based case-control study that
was initiated in 1996 and that encompasses incident
cases of early RA from a geographically defined area in
Sweden. For each case, a control subject was randomly
selected from the Swedish national population registry,
matched for age, sex, and residential area. In this study,
we investigated 1,786 RA cases and 1,029 controls
which were included in EIRA from 1996 to 2004 and
had available DNA (88% of all participant cases and
matched controls). All cases fulfilled the American Col-
lege of Rheumatology 1987 criteria for the classification
of RA. All participants gave informed consent and
answered a questionnaire that included detailed infor-
mation on environmental exposures. The cases and con-
trols were classified according to their smoking habits
into never or ever smokers (not available for 3% of the
participants). The study was approved by the ethical
review board of the Karolinska Institute.
Replication study: extended Icelandic rheumatoid arthritis
families
A replication study was performed in 74 extended Ice-
landic RA families, which have been described in detail
in a previous report [12]. From the 210 RA patients and
406 first-degree relatives in the families, information
about smoking habits was available for 53%. RF had
been measured in all participants by using standard pro-
cedures, as previously described [24].
Definition of variables
RF status was determined by using standard procedures
and ACPAs by standard ELISA (Immunoscan-RA
Mark2 ELISA test; Euro-Diagnostica, Malmö, Sweden).
RF status was missing for 9%, and ACPA status was not
available for 6%. The methods for determining the
HLA-DRB1 SE alleles and the PTPN22*R620W (1858C/
T) polymorphism have been previously reported
[3,4,25]. Carriage of SE and the PTPN22*620W could
not be defined for 1.2% and 1.7%, respectively.
MBL status was defined on the basis of genotyping in
EIRA and serum levels in the extended RA families.
MBL serum levels were measured by a sandwich ELISA
system as previously described [19]. In EIRA, four sin-
gle-nucleotide polymorphisms in the MBL2 gene were
genotyped with two different methods. One regulatory
MBL2 promoter polymorphism, influencing the produc-
tion of MBL (rs7096206 in position -221, C/G, which is
often referred to as minor allele X versus major allele
Y), was genotyped by TaqMan allelic discrimination
assay on a 384-well plate in accordance with recommen-
dations of the manufacturer (Applied Biosystems, Foster
City, CA, USA) (missing for 3.8%). By means of the pyr-
osequencing platform, a modified method from Roos
and colleagues [26] was used on a 96-well plate (Supple-
mentary Text 1). Three structural polymorphisms within
exon-1, which interrupt the polymerization of the pro-
tein, were analyzed: rs5030737 in codon 52 (C/T or
minor allele called D versus A), rs1800450 (codon 54,
A/G or minor allele B versus A), and rs1800451 (codon
57, A/G or minor allele C versus A). This method is
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preferable to TaqMan for the exon-1 polymorphisms as
they are so close to each other.
Construction of a functional mannan-binding lectin
genotype
To construct a functionally relevant genotype, the three
minor alleles within exon-1 are pooled and referred to
as 0 as opposed to A when not carrying any of these
three minor alleles. The minor allele of the promoter
polymorphism (referred to as X as opposed to the high-
level-producing Y allele) always exists with major alleles
(A) of all the exon-1 polymorphisms [9]. Therefore, only
the following haplotypes are observed; XA, YA, YB, YC,
or YD. YB, YC, and YD are pooled together and referred
to as 0, as they result in similar MBL serum levels and
only one can be present. Four individuals (0.1%)
deviated from these known haplotypes (that is, genotype
showed X together with B, C, or D) and were excluded.
All detected genotypes were in Hardy-Weinberg equili-
brium. A full composite functional MBL genotype was
available for 2,586 of the 2,815 participants (YA/YA,
YA/XA, XA/XA, 0/YA, 0/XA, or 0/0).
Statistical analysis
Multivariate logistic regression was used to calculate
odds ratios (ORs) with 95% confidence intervals (CIs) of
carrying the MBL-high as compared with the MBL-low
genotype, adjusted for age, sex, and residence of cases
and controls. Additional analyses were performed by
adding SE, PTPN22*620W, and smoking to the model.
The Mann-Whitney test was used to compare continu-
ous MBL levels between groups as they are not normally
distributed. Statistical analyses were performed with SAS
9.1 software (SAS Institute Inc., Cary, NC, USA).
Results
Baseline characteristics
The EIRA study represents a typical early RA cohort.
Seventy percent of the patients were female, the median
age was 54 years (16 to 82), 66% were RF-positive, and
61% were ACPA-positive. Seventy percent of the cases
and 65% of the age-, gender-, and geographic-location-
matched controls had ever smoked.
Allele frequencies of the four polymorphisms in the
MBL2 gene were in accordance with those reported
from other Caucasian populations (Table 1). Variants
that are known to be associated with MBL serum levels
above and below the median population level (approxi-
mately 1,000 μg/L) were grouped together in function-
ally meaningful genotypes (see Materials and methods),
and these were the basis for all analyses shown. MBL-
high genotype (n = 1,330) refers to those with a major
allele of all exon-1 polymorphisms, referred to as A/A,
excluding homozygosity for the low-producing minor
promoter allele (referred to as XA/XA). In the MBL-low
genotype (n = 1,256), those genotypes that are asso-
ciated with intermediate or deficient levels of MBL are
pooled, including those with homo- or heterozygosity
for the minor alleles of the exon-1 polymorphisms (0/0),
referred to as 0/0, 0/YA and 0/XA, as well as those who
are homozygous for the minor promoter allele (XA/XA).
Does high mannan-binding lectin predispose to
rheumatoid arthritis as a whole?
In the study group as a whole, no association was
observed between MBL-high, as compared with MBL-
low genotype, and RA (OR 1.03, 95% CI 0.87 to 1.21).
Nor was any association between MBL-high genotype
and RA observed when the association estimate was
Table 1 Allele frequencies of the whole EIRA study group
Position Genotypea Cases Controls
Promoter/-221 nt (rs 7096206)
CC (YY) 1,130 609
CG (XY) 542 310
GG (XX) 65 51
Missing 49 59
Exon 1
Codon 52/223 nt (rs 5030737)
CC (AA) 1,420 826
CT (AD) 282 148
TT (DD) 14 10
Missing 70 45
Codon 54/230 nt (rs 1800450)
GG (AA) 1,253 701
AG (AB) 422 257
AA (BB) 41 26
Missing 70 45
Codon 57/239 nt (rs 1800451)
GG (AA) 1,643 955
AG (AC) 71 29
AA (CC) 2 0
Missing 70 45
Exon 1 haplotype
Wild-type A/A 947 544
Heterozygous 0/A 657 373
Homozygous 0/0 112 67
Missing 70 45
Functional MBL genotypeb
High YA/YA+YA/XA 863 467
Low YA/0, 0/0, XA/0, XA/XA 803 453
Missing 120 109
aThe nomenclature of the mannan-binding lectin (MBL) literature is shown
within parentheses. b0 refers to carrying any one of the exon 1 minor alleles
(B, C, or D) and A is the major allele. The promoter minor allele X is in linkage
equilibrium with the A major allele of exon 1. 0/0 refers to DD, BB, CC, or
compound heterozygotes: BD, BC, or CD. EIRA, Epidemiological Investigation
of Rheumatoid Arthritis.
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adjusted for three established risk factors for RA (smok-
ing, SE, and PTPN22*620W) in the multivariate model
(adjusted OR 0.99, 95% CI 0.83 to 1.18), but as
expected, these risk factors were significantly associated
with RA (ever smoking: adjusted OR 1.39, 95% CI 1.17
to 1.67; SE: adjusted OR 2.76, 95% CI 2.32 to 3.28; and
PTPN22*620W: adjusted OR 1.47, 95% CI 1.21 to 1.79).
Stratification by serological status
Next, to evaluate whether the MBL-high genotype might
be a risk factor for a certain subgroup of the criteria-
based syndrome (Table 2), the study group was stratified
according to RF and ACPA status. Then, a non-signifi-
cant trend association was observed for RF-negative RA
(OR 1.20, 95% CI 0.96 to 1.51), whereas no association
was observed for RF-positive RA (OR 1.00, 95% CI 0.83
to 1.20). No significant associations were observed when
stratified for ACPA status alone (Table 2), but interest-
ingly, the MBL-high genotype tended to be associated
with the RF-negative/ACPA-positive subgroup of RA
(OR 1.54, 95% CI 0.99 to 2.38) rather than the RF-nega-
tive/ACPA-negative subgroup (OR 1.14, 95% CI 0.89 to
1.47).
Stratification by smoking status
When the same exercise was performed after stratifica-
tion by smoking status, the trend association observed
between MBL-high genotype and RF-negative RA turned
out to be confined to never smokers (OR 1.82, 95% CI
1.24 to 2.69) whereas no association was observed in
ever smokers (OR 0.96, 95% CI 0.73 to 1.28). The asso-
ciation in never smokers was significant for both the
RF-negative/ACPA-positive subgroup of RA (OR 3.07,
95% CI 1.37 to 6.89) and the RF-negative/ACPA-nega-
tive subgroup (OR 1.67, 95% CI 1.10 to 2.55). This was
also significant for the whole ACPA-positive subgroup
on a never-smoking background (OR 1.55, 95% CI 1.08
to 2.23), and a trend was observed for ACPA-negative
RA (OR 1.42, 95% CI 0.98 to 2.05). Subgrouping of ever
smokers by serological status yielded no significant asso-
ciations between MBL-high genotype and RA (Table 2).
In fact, the association between the MBL-high geno-
type and RA was significant for the never-smoking
group as a whole (Table 2), irrespectively of serological
status (OR 1.39, 95% CI 1.04 to 1.85). From a more
functional angle, never-smoking RA patients carrying
the MBL-high genotype were less likely to be RF-posi-
tive (52%) as compared with patients carrying the MBL-
low genotype (63%, OR 0.65, 95% CI 0.44 to 0.97), but
no difference was observed in ever smokers (69% versus
70%). The proportion of ACPA-positive patients was
similar in never-smoking RA patients carrying the MBL-
high and MBL-low genotype (52% and 53%).
Stratification by genetic risk factors
Then, we wanted to see, in the context of smoking sta-
tus, whether there was an interaction between the MBL-
high genotype and SE, the main genetic risk factor iden-
tified for RA. In Figure 1, the subgroups of autoanti-
body-positive and -negative disease are shown
separately: RF-positive versus -negative (Figure 1a,b) and
ACPA-positive versus -negative (Figure 1c,d), respec-
tively. Never smokers not carrying the SE and the MBL-
high genotype served as the referent group. As pre-
viously reported, carrying the SE was a strong risk factor
for RF-positive but not for RF-negative RA. However,
Table 2 Rheumatoid arthritis risk associated with MBL-high genotype in the whole EIRA study group and stratified for
serology and smoking status
Whole group Never smokers Ever smokers
Number of cases/controls OR (95% CI)a OR (95% CI)a OR (95% CI)a
Whole group 1,666/920 1.03 (0.87-1.21) 1.39 (1.04-1.85) 0.83 (0.67-1.04)
Stratification by serological status
Seronegative
RF- 476/920 1.20 (0.96-1.51) 1.82 (1.24-2.69) 0.96 (0.73-1.28)
ACPA- 585/920 1.03 (0.83-1.27) 1.42 (0.98-2.05) 0.77 (0.58-1.04)
RF-/ACPA- 361/920 1.14 (0.89-1.47) 1.67 (1.10-2.55) 0.80 (0.56-1.13)
RF-/ACPA+b 105/920 1.54 (0.99-2.38) 3.07 (1.37-6.89) 1.06 (0.57-1.99)
Seropositive
RF+ 925/920 1.00 (0.83-1.20) 1.26 (0.89-1.78) 0.86 (0.68-1.10)
ACPA+ 916/920 1.08 (0.89-1.30) 1.55 (1.08-2.23) 0.88 (0.69-1.13)
RF+/ACPA-c 172/920 0.83 (0.59-1.17) 0.96 (0.53-1.74) 0.74 (0.47-1.17)
RF+/ACPA+ 744/920 1.06 (0.87-1.29) 1.42 (0.97-2.10) 0.90 (0.70-1.16)
aRisk was calculated as odds ratios (ORs) with 95% confidence intervals (CIs) adjusted for age, sex, and geographic location by using logistic regression. bIn the
ACPA+ group, 20% of never smokers and 10% of smokers were RF-: OR 2.07 (1.36 to 3.14), P = 0.0005. cIn the RF+ group, 24% of never smokers and 17% of
smokers were ACPA-: OR 1.58 (1.11 to 2.25), P = 0.01. ACPA, anti-citrullinated protein antibody; EIRA, Epidemiological Investigation of Rheumatoid Arthritis; MBL,
mannan-binding lectin; RF, rheumatoid factor.
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the MBL-high genotype was associated with a double
risk of RF-negative RA in never smokers, but this was
significant on an SE-negative background only. An over-
all similar pattern was observed in the ACPA-positive
(Figure 1c) and ACPA-negative (Figure 1d) subgroups,
although the MBL-high genotype was significantly asso-
ciated with both subgroups on an SE-negative back-
ground in never smokers. A similar pattern was
observed when stratified for the PTPN22*620W risk
allele instead of SE (Figure 2).
Additional evidence from a family study
As we have previously reported higher MBL levels in RA
patients than in their first-degree relatives in Icelandic
families [12], we went back to the families and re-ana-
lyzed the data for those 53% who had available informa-
tion about smoking (106 RA patients and 210 first-
degree relatives). Patients with or without information
about smoking habits did not differ with respect to
MBL levels (P = 0.5), age (P = 0.5), sex (P = 0.2), or RF
positivity (P = 0.2). Furthermore, a similar difference
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Figure 1 Risk of developing rheumatoid arthritis in subjects exposed to different combinations of cigarette smoking status (never or
ever smoker), MBL-high genotype, and the ‘shared epitope’. Subjects were stratified by the presence of rheumatoid factor (a,b) or anti-
citrullinated protein antibodies (c,d). Risk is calculated as odds ratios by using logistic regression adjusted for age, sex, and geographic location.
*Significant 95% confidence interval. ACPA, anti-citrullinated peptide antibody; MBL, mannan-binding lectin; RF, rheumatoid factor; SE, shared
epitope.
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was observed in MBL levels between RA patients and
first-degree relatives who did not have information
about smoking status (1,605 versus 989 μg/L; P = 0.11)
as in those who did (1,573 versus 1,202 μg/L; P = 0.03).
RF status was available for all patients, and 65% were
RF-positive. Of these, 80% of the RA patients and 59%
of their non-RA first-degree relatives were ever smokers
(OR 2.72, 95% CI 1.57 to 4.70). As a MBL serum level
of 1,000 μg/L is reported to distinguish fairly well
between individuals with MBL-high and MBL-low geno-
types, this cutoff was used for comparison as in the pre-
vious report. It was previously reported that patients
with RA had higher MBL levels than their first-degree
relatives. No significant association was observed when
stratified for RF status into RF-positive disease (OR 1.25,
95% CI 0.72 to 2.19) and RF-negative disease (OR 1.40,
95% CI 0.67 to 2.89). When MBL levels were compared
as a continuous variable, RF-negative RA patients
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Figure 2 Risk of developing rheumatoid arthritis in subjects exposed to different combinations of cigarette smoking status (never or
ever smoker), MBL-high genotype, and the PTPN22*620W risk allele. Subjects were stratified by the presence of rheumatoid factor (a,b) or
anti-citrullinated protein antibodies (c,d). Risk is calculated as odds ratios by using logistic regression adjusted for age, sex, and geographic
location. *Significant 95% confidence interval. ACPA, anti-citrullinated peptide antibody; MBL, mannan-binding lectin; RF, rheumatoid factor.
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tended to have higher MBL levels than relatives (Figure
3a; P = 0.07), but the findings were less significant when
the larger group of RF-positive RA patients was com-
pared with relatives (Figure 3b; P = 0.11).
However, when stratified for smoking status and ana-
lyzed with the 1,000 μg/L cutoff, the reported associa-
tion turned out to be limited to the never smokers (OR
2.40, 95% CI 1.05 to 5.51), whereas no association was
observed in ever smokers (OR 0.92, 95% CI 0.50 to
1.69). This was also observed when MBL levels were
compared as a continuous variable, where never-smok-
ing patients with RA had a median level two times
higher than that of the relatives (Figure 3c; P = 0.007),
whereas no difference was observed in ever smokers
(Figure 3d; P = 0.5). When the never-smoking group
was stratified further according to RF status, the MBL
levels were also significantly higher in RF-negative RA
patients than in the first-degree relatives (2,068 versus
1,086 μg/L; P = 0.036). Thus, these findings are similar
to those in the EIRA study.
Discussion
Our results indicate that functionally important genetic
variations of the MBL2 gene, or high MBL levels, are
associated with RF-negative RA, but only in individuals
who have never smoked. These findings were detected
in the EIRA case-control study and confirmed in a sepa-
rate independent family-based study, in which high
MBL was previously found to be associated with RA as
a whole. This highlights the importance of careful sub-
grouping of the criteria-based clinical syndrome of RA
since risk associations that exist only in subgroups of
patients may otherwise not be detected. Thus, carrying
the MBL-high genotype seems to double the risk of RF-
negative RA in never smokers, namely a subgroup in
which the main established genetic risk factors (SE and
the PTPN22*620W allele) do not play a significant role.
Analyzing this subset further by taking away those car-
rying the SE or PTPN22*620W allele showed an even
stronger association with the MBL-high genotype, indi-
cating that the pathogenic mechanisms involving MBL
are not dependent on these variants.
These findings may explain those in previous studies,
in which no association was observed between high
MBL levels or associated genotypes and the risk of RA
[14-19]. However, previous findings in the extended RA
families, in which RA patients had higher MBL levels
than their first-degree relatives, turned out to be limited
to the never smokers, particularly the RF-negative sub-
group [12]. Whether or to what extent smoking status
might explain previous contradictory findings remains
to be elucidated.
Given these results, high MBL is unlikely to play a
role in the etiology of RF-positive RA, in which
smoking, SE, and PTPN22*620W are well-known envir-
onmental and genetic risk factors [3-5]. MBL may, on
the other hand, have a role in the pathogenesis of RF-
negative disease but only in the absence of smoking as
an environmental trigger. This is particularly interesting
as the recent genome-wide association studies have
yielded sparse results for RF-negative RA [6]. Actually,
the findings in previous publications indicated that RF
positivity is more frequent in those with lower MBL
levels [19,23], and similar non-significant findings have
been observed for MBL-low genotypes [15,22], but no
previous report has compared RF-positive and -negative
patients with controls separately.
Among the strengths of this study is the large, popula-
tion-based recruitment of early RA cases and carefully
matched controls. The participation rate was high, and
detailed information about smoking status and validated
genetic risk factors was available. The findings were
then replicated in another independent Caucasian popu-
lation in an extensive Icelandic family-based study, in
which patients were compared with their first-degree
relatives. This should minimize the potential confound-
ing effect of genetic heterogeneity and environmental
factors. The first study was based on a genotype (MBL-
high genotype) known from previous studies to predict
a certain phenotype (MBL levels above the median
population level), whereas the replication study was
based on the phenotype itself, namely the serum levels
of the MBL protein, thus illustrating the functional rele-
vance of these findings. In the family-based study, infor-
mation about smoking was available for only 53% of the
participants. Nevertheless, findings similar to those of
the EIRA study were observed in the family study;
namely, the previously reported association was, in fact,
confined to the never-smoking group. Thus, the findings
indicate that smoking somehow hinders the function of
MBL.
Possible speculation why association is more consis-
tent in non-smokers may be based on the hypothesis
that MBL is inactivated in smokers. In accordance with
this hypothesis, 65% of RF-negative RA patients but
only 1.6% of controls have been reported to have anti-
MBL antibodies, and in a later study, the authors found
MBL to be S-nitrosylated (SNO-MBL) in a majority of
the RA patients [27,28]. These antibodies are likely to
influence the major function of MBL: its ability to opso-
nize apoptotic debris and microorganisms and to acti-
vate the complement system. Additionally, synovial fluid
from RA patients is able to induce S-nitrosylation
(SNO) of MBL, and anti-SNO-MBL was shown to be
higher in synovial fluid than in serum [27,28]. Thus,
post-translational modification of MBL by SNO may
induce autoantibody production, which in turn may hin-
der its function. As cigarette smoke is the strongest
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Figure 3 MBL levels of rheumatoid arthritis patients from extended Icelandic families compared with their first-degree relatives.
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known exogenous nitrosylating agent in the body
[29,30], it is plausible that smoking inhibits the MBL
function through nitrosylation by itself without involve-
ment of autoantibody, and therefore, the risk of RA
associated with MBL-high genotypes is observed only in
never smokers.
Although the association with the MBL-high genotype
was confined mostly to the RF-negative subgroup, simi-
lar findings were observed within both the ACPA-posi-
tive and -negative subgroups. Therefore, we dissected
this further into subgroups according to both RF and
ACPA status and found the association in the RF-nega-
tive subgroup to be significant in both those with and
those without ACPA. Although this study was not
designed to elucidate pathogenic mechanisms, a plausi-
ble explanation for this may lie in the inherent differ-
ence between these two autoantibody markers. ACPA
binds citrullinated structures and is quite specific for
RA, whereas RF is an anti-antibody that builds immune
complexes and is observed in a substantial proportion of
patients with other inflammatory diseases and healthy
controls. Smoking induces RF production in healthy
individuals [31] but can also lead to citrullination of
lung structures and thereby trigger ACPA production in
RA patients carrying a vulnerable genetic background
[32]. MBL can bind to antibodies, including agalactosy-
lated IgG (which is increased in RA patients), IgA, cer-
tain IgM isoforms, and immune complexes [8,33-35].
This supports the notion that MBL-mediated clearance
of antibodies and immune complexes might diminish
the likelihood of RF production and thereby seropositiv-
ity. As a pattern recognition receptor that has multiple
binding sites, MBL has presumably higher affinity to
immune complexes than single-antibody particles. It has
been reported that patients with high MBL levels are
less likely to be RF-positive [19,23], a finding that we
could confirm in the never-smoking group of the EIRA
study, whereas no difference was observed among smo-
kers. Given this finding and the current literature, we
hypothezise that MBL mediates the clearance of circu-
lating immune complexes (and perhaps RF) from the
blood but that, within confined spaces like the joint,
MBL may lead to complement-mediated inflammation
after binding to immune complexes, resulting in the
syndrome of RF-negative RA.
Conclusions
In a population-based case-control study and also in an
extended family study, we have found that the MBL-
high genotype or high levels of its product, the MBL
protein, are associated with RF-negative RA in those
who have never smoked. This highlights the importance
of careful subgrouping of the criteria-based clinical
syndrome of RA, as risk associations that exist only in
subgroups of patients may otherwise not be detected.
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